Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) Stock Competitors & Peer Comparison

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, RPRX has a market cap of 27.2B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while RPRX trades at $61.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 11.68. In terms of profitability, CPD's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CPD is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for CPD.Check RPRX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CORT has a market cap of 13.1B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CORT trades at $122.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 345.86. In terms of profitability, CPD's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, CPD is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CORT's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, CPD's ROE is N/A, compared to WBA's ROE of -0.42%. Regarding short-term risk, CPD is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CPD.Check WBA's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, LQDA has a market cap of 6.1B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while LQDA trades at $68.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 490.14. In terms of profitability, CPD's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CPD is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for CPD.Check LQDA's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while KNSA trades at $79.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 87.81. In terms of profitability, CPD's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CPD is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for CPD.Check KNSA's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while PBH trades at $51.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas PBH's P/E ratio is 11.61. In terms of profitability, CPD's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, CPD is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for CPD.Check PBH's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CPD is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CPD.Check HROWL's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while LTGO trades at $22.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas LTGO's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, CPD is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CPD.Check LTGO's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas HROWM's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CPD is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CPD.Check HROWM's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, HELP has a market cap of 780.4M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while HELP trades at $12.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas HELP's P/E ratio is -3.02. In terms of profitability, CPD's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, CPD is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CPD.Check HELP's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SVA's P/E ratio is -5.68. In terms of profitability, CPD's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, CPD is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CPD.Check SVA's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CUVL has a market cap of 390.3M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CUVL trades at $7.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, CPD is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CUVL's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, HITI has a market cap of 215.3M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while HITI trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas HITI's P/E ratio is 61.25. In terms of profitability, CPD's ROE is N/A, compared to HITI's ROE of -0.43%. Regarding short-term risk, CPD is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for CPD.Check HITI's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CPD is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CELG-RI's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CPD's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CPD is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CPD.Check ATLN's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CTOR trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -1.62. In terms of profitability, CPD's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CPD is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CTOR's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SDEV has a market cap of 57M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SDEV trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.20. In terms of profitability, CPD's ROE is N/A, compared to SDEV's ROE of +7.90%. Regarding short-term risk, CPD is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for CPD.Check SDEV's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, CPD's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, CPD is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CPD.Check RAD's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CPD's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CPD is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CPD.Check GLTO's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, NSRX has a market cap of 34.5M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while NSRX trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -5.56. In terms of profitability, CPD's ROE is N/A, compared to NSRX's ROE of +0.00%. Regarding short-term risk, CPD is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CPD.Check NSRX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SCYX has a market cap of 32.1M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SCYX trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.49. In terms of profitability, CPD's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CPD is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for CPD.Check SCYX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CNSY has a market cap of 20.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CNSY trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.42. In terms of profitability, CPD's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CPD is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CNSY's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, BFRI has a market cap of 18.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while BFRI trades at $1.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -2.69. In terms of profitability, CPD's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CPD is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CPD.Check BFRI's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, BFRIW has a market cap of 16.7M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, CPD's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CPD is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CPD.Check BFRIW's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, COSM has a market cap of 11.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.29. In terms of profitability, CPD's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, CPD is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CPD.Check COSM's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CPD's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CPD is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CPD.Check CJJD's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, CPD's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, CPD is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CPD.Check SSY's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, POM has a market cap of 6.5M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while POM trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.19. In terms of profitability, CPD's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, CPD is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CPD.Check POM's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while BGMS trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.25. In terms of profitability, CPD's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CPD is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for CPD.Check BGMS's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, PAVS has a market cap of 4.3M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while PAVS trades at $5.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.06. In terms of profitability, CPD's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CPD is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CPD.Check PAVS's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CPD's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CPD is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CPD.Check MDVL's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CPD is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CPD.Check ATNFW's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CPD's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CPD is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CPD.Check BGMSP's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CPD's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CPD is less volatile compared to AZNH. This indicates lower risk in terms of short-term price fluctuations for CPD.Check AZNH's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, PRPH has a market cap of 346.2K. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while PRPH trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas PRPH's P/E ratio is -0.01. In terms of profitability, CPD's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CPD is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CPD.Check PRPH's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CPD's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CPD is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CPD.Check LFLYW's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CPD's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CPD is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CPD.Check IPXL's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, POZN has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, CPD's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, CPD is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CPD.Check POZN's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, OREX has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, CPD's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, CPD is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CPD.Check OREX's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CPD's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CPD is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CPD.Check SHPG's competition here

Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CPD stands at 0. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CPD is priced at $5.25 on the AMEX, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CPD currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CPD's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CPD is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CPD.Check ESRX's competition here